NRAS and melanoma: Treatment of NRAS-mutant melanoma cells with MEK and CDK4/6 inhibitors induced two divergent drug responses: fast-adapting cells characterised by increased ion transmembrane transport and an immune-like state, and slow-adapting cells with features of senescence.53